Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01246700
Other study ID # 225510
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 22, 2010
Last updated November 22, 2010
Start date June 2008
Est. completion date December 2010

Study information

Verified date September 2010
Source Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Contact n/a
Is FDA regulated No
Health authority Canada: Wilfrid Laurier University Board of Ethics - REB
Study type Interventional

Clinical Trial Summary

The purpose of this study is 1.) to determine if sensory attention focused exercise is an effective management strategy for Parkinson's disease, and 2.) to identify if the benefits are a result of strength gains.


Description:

Currently, there is no cure for Parkinson's disease (PD) and although medication offers symptom reduction, there are many negative side effects associated with medication use. Thus, there has been an increased emphasis on exercise interventions for symptom reduction. Recent research has shown that both sensory attention focused exercise (SAFEx) and strength training interventions improved disease severity more so than other exercise interventions (such as aerobic, aquatic and no exercise). Upon closer examination, SAFEx showed further symptom improvements than the strength training program. Thus exists the need to further examine SAFEx using a standardized protocol - a single-blind randomized double-crossover trial - that has been used sparingly in exercise interventions. In addition, the 30-second chair stand has been implemented into the testing protocol, as it has been shown to be a reliable measurement of functional strength for older adults. This test was implemented in order to identify the functional strength gains, if any, that are associated with SAFEx. It is hypothesized that the SAFEx intervention will improve disease symptoms in PD, and that the results will not be due to strength gains.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 76
Est. completion date December 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- diagnosis of PD by a clinician/neurologist

- absence of mentation

- established medication schedule and dosage

Exclusion Criteria:

- mentation

- change in medication during period of study

- change in exercise level during period of study

- inability to complete the exercise program

- absence of 5 or more classes, or absence of 3 or more classes in sequence

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Sensory Attention Focused Exercise (SAFEx)
Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs. Group A received SAFEx for 12 weeks then received no treatment for 12 weeks.
Sensory Attention Focused Exercise (SAFEx)
Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs. Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks.

Locations

Country Name City State
Canada Sun Life Financial Movement Disorders Research and Rehabilitation Centre Waterloo Ontario

Sponsors (5)

Lead Sponsor Collaborator
Sun Life Financial Movement Disorders Research and Rehabilitation Centre Canada, Sun Life Financial, Canada, Young Men's Christian Association (YMCA), Canadian Institutes of Health Research (CIHR), Parkinson Society Canada

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar;44(3 Pt 1):376-8. — View Citation

Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, Chavret F, Hetherington V, Baker K, Lim I. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):134-40. Erratum in: J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1414. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):126. — View Citation

Sage MD, Almeida QJ. A positive influence of vision on motor symptoms during sensory attention focused exercise for Parkinson's disease. Mov Disord. 2010 Jan 15;25(1):64-9. doi: 10.1002/mds.22886. — View Citation

Sage MD, Almeida QJ. Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease. Mov Disord. 2009 Jun 15;24(8):1132-8. doi: 10.1002/mds.22469. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Unified Parkinson's Disease Rating Scale (UPDRS) III (motor score) Assessment of patient's disease severity, completed by a blinded certified clinician. Baseline, 12 weeks and 24 weeks No
Secondary Timed up and go Participants stand out of a chair, walk 3 meters, turn around and sit back down. This task is timed. Baseline, 12 weeks and 24 weeks No
Secondary 30 second chair stand Participants instructed to stand from a seated position as many times as possible in 30 seconds. Number of completed stands is recorded. Baseline, 12 weeks and 24 weeks No
Secondary Unified Parkinson's Disease Rating Scale (UPDRS) - I and II (self report of mentation, depression, and activities of daily living). Participants complete a self-report questionnaire, and rank how they are feeling. Baseline, 12 weeks and 24 weeks No
Secondary Grooved Pegboard Participants must place and remove 25 pegs as fast as possible using a standard Grooved Pegboard. Participants are timed. Baseline, 12 weeks and 24 weeks No
Secondary Step Length Measured using GAITRite software. Baseline, 12 weeks and 24 weeks No
Secondary Velocity Assessed using GAITRite software. Baseline, 12 weeks and 24 weeks No
Secondary Step to Step Length Variability Assessed using GAITRite software. Baseline, 12 weeks and 24 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02927691 - Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial Phase 2
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A